Trials / Recruiting
RecruitingNCT05760378
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
An Open, Randomized Phase III Study of Famitinib With Camrelizumab Plus Treatment of Physician's Choice (TPC) Versus Camrelizumab Plus TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic Triple-negative Breast Cancer
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 223 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the Famitinib with Camrelizumab plus treatment of physician's choice (TPC) versus Camrelizumab plus TPC in Patients with Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Famitinib | TKI |
| DRUG | Camrelizumab | PD1 inhibitor |
| DRUG | nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin | TPC |
Timeline
- Start date
- 2023-03-17
- Primary completion
- 2025-01-01
- Completion
- 2027-01-01
- First posted
- 2023-03-08
- Last updated
- 2024-02-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05760378. Inclusion in this directory is not an endorsement.